MANE
$61.07
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's p...
Recent News
Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal?
If you are trying to work out whether Veradermics at around US$50.65 is offering good value or asking too much, you are in the right place. Over the short term, the stock has posted returns of 12.4% over 7 days, 31.6% over 30 days and 34.2% year to date, which can change how investors think about both upside potential and risk. Recent news around Veradermics has focused on its position in the pharmaceuticals and biotech space and investor interest in its prospects, which helps explain why...
Flagship-Backed Generate Biomedicines Raises $400 Million in IPO
The Somerville, Massachusetts-based drug developer sold 25 million shares for $16 each, according to a statement Thursday. Generate was offering the shares for $15 to $17 apiece, according to its earlier filings with the US Securities and Exchange Commission. At the IPO price, Generate would have a market value of about $2 billion based on the outstanding shares listed in its filings.
For the first time in decades, new hair-loss treatments are in the works. Here’s how they’re different.
“Botox on steroids”: Old hair-loss drugs are getting an upgrade, and new ones are on the way.
Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue Losses
Veradermics (MANE) has drawn investor attention after recent trading left the shares at $37.03, with a 1 day return of 3.77% and a year to date decline of 1.91%. See our latest analysis for Veradermics. Veradermics' recent 1 day share price return of 3.77% comes after a year to date share price return decline of 1.91%. This suggests short term momentum has picked up slightly even as investors continue to reassess risk around its development pipeline and lack of current revenue. If this move...
Jennifer Garner’s Once Upon a Farm Rises Nearly 20% to Wrap Up Busy Week for IPOs
Jennifer Garner’s Sidney Bristow character from the TV show Alias and Elektra in Marvel movies may have faced formidable foes. Garner is a co-founder and investor in the organic baby food company Once Upon a Farm which began trading Friday after a rocky week for the market and initial public offerings. Once Upon a Farm priced the IPO at $18, the midpoint of its expected range.